Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:6591717.
doi: 10.1155/2016/6591717. Epub 2016 Sep 8.

Platelet-Rich Plasma: The Choice of Activation Method Affects the Release of Bioactive Molecules

Carola Cavallo  1 , Alice Roffi  2 , Brunella Grigolo  1 , Erminia Mariani  3 , Loredana Pratelli  4 , Giulia Merli  2 , Elizaveta Kon  5 , Maurilio Marcacci  5 , Giuseppe Filardo  6
Affiliations

Platelet-Rich Plasma: The Choice of Activation Method Affects the Release of Bioactive Molecules

Carola Cavallo et al. Biomed Res Int. 2016.

Abstract

Platelet-Rich Plasma (PRP) is a low-cost procedure to deliver high concentrations of autologous growth factors (GFs). Platelet activation is a crucial step that might influence the availability of bioactive molecules and therefore tissue healing. Activation of PRP from ten voluntary healthy males was performed by adding 10% of CaCl2, 10% of autologous thrombin, 10% of a mixture of CaCl2 + thrombin, and 10% of collagen type I. Blood derivatives were incubated for 15 and 30 minutes and 1, 2, and 24 hours and samples were evaluated for the release of VEGF, TGF-β1, PDGF-AB, IL-1β, and TNF-α. PRP activated with CaCl2, thrombin, and CaCl2/thrombin formed clots detected from the 15-minute evaluation, whereas in collagen-type-I-activated samples no clot formation was noticed. Collagen type I produced an overall lower GF release. Thrombin, CaCl2/thrombin, and collagen type I activated PRPs showed an immediate release of PDGF and TGF-β1 that remained stable over time, whereas VEGF showed an increasing trend from 15 minutes up to 24 hours. CaCl2 induced a progressive release of GFs from 15 minutes and increasing up to 24 hours. The method chosen to activate PRP influences both its physical form and the releasate in terms of GF amount and release kinetic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clot formation at 24 h in the different activation groups.
Figure 2
Figure 2
TGF, PDGF, and VEGF release kinetics according to the activation method.
See this image and copyright information in PMC

References

    1. Kon E., Filardo G., Di Martino A., Marcacci M. Platelet-rich plasma (PRP) to treat sports injuries: evidence to support its use. Knee Surgery, Sports Traumatology, Arthroscopy. 2011;19(4):516–527. doi: 10.1007/s00167-010-1306-y. - DOI - PubMed
    1. Tschon M., Fini M., Giardino R., et al. Lights and shadows concerning platelet products for musculoskeletal regeneration. Frontiers in Bioscience-Elite. 2011;3(1):96–107. - PubMed
    1. Andriolo L., Di Matteo B., Kon E., Filardo G., Venieri G., Marcacci M. PRP augmentation for ACL reconstruction. BioMed Research International. 2015;2015:15. doi: 10.1155/2015/371746.371746 - DOI - PMC - PubMed
    1. Del Fabbro M., Gallesio G., Mozzati M. Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. European Journal of Cancer. 2015;51(1):62–74. doi: 10.1016/j.ejca.2014.10.015. - DOI - PubMed
    1. Filardo G., Kon E., Roffi A., Di Matteo B., Merli M. L., Marcacci M. Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surgery, Sports Traumatology, Arthroscopy. 2015;23(9):2459–2474. doi: 10.1007/s00167-013-2743-1. - DOI - PMC - PubMed